Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus ADT in Castrate Sensitive Prostate Carcinoma
NCT01377389Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2011
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2011; status: terminated.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01377389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377389.